Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma. Editorial Article uri icon

Overview

publication date

  • December 17, 2018

Research

keywords

  • Antineoplastic Agents
  • Molecular Targeted Therapy
  • Urinary Bladder Neoplasms

Identity

Scopus Document Identifier

  • 85058702048

Digital Object Identifier (DOI)

  • 10.1080/14728222.2019.1559828

PubMed ID

  • 30558440

Additional Document Info

volume

  • 23

issue

  • 2